GE HealthCare to Acquire SOFIE Biosciences for $945 Million: What It Means for PET Radiopharmaceutical Supply in the U.S.
In brief: GE HealthCare has agreed to buy SOFIE Biosciences, a major U.S. contract manufacturer of PET radiopharmaceuticals, in an all-cash deal worth $945 million. The acquisition gives GE HealthCare a presence in the “final mile” of PET drug supply, the time-sensitive step that gets short-lived imaging agents to hospitals and imaging centers. It also gives the company U.S. rights to FAPI-74, a Phase III cancer imaging candidate.
Key Takeaways
- Deal value: $945 million in cash, with SOFIE Biosciences acquired from private equity firm Trilantic North America.
- Timeline: The deal was announced on October 5, 2026, and is expected to close in the first half of 2027, pending regulatory approvals and other closing conditions.
- Network: SOFIE operates 15 U.S. manufacturing sites with 21 cyclotrons, plus a theranostics-focused CDMO site.
- Pipeline asset: The deal adds U.S. rights to FAPI-74, a Phase III PET radiotracer with pan-cancer imaging potential.
- Business as usual: SOFIE will keep supplying PET products from other radiopharmaceutical companies after the deal closes.
What Is Happening in the GE HealthCare and SOFIE Biosciences Deal?
GE HealthCare (Nasdaq: GEHC) signed a definitive agreement to acquire SOFIE Biosciences, a leading U.S. contract manufacturing organization (CMO) for PET radiopharmaceuticals. Once the transaction closes, SOFIE will join GE HealthCare’s Pharmaceutical Diagnostics (PDx) segment.
GE HealthCare expects the deal to boost revenue growth, Adjusted EBIT margin and Adjusted earnings per share in the first full year of ownership. It also expects SOFIE to grow at a low double-digit rate under its ownership.
Why the “Final Mile” of PET Radiopharmaceutical Supply Matters
Most medicines can sit on a shelf for months. Many PET imaging agents cannot. Fluorine-18 (F18) radiopharmaceuticals have a half-life of about 110 minutes, meaning their radioactivity declines quickly after production. They must be made close to where patients are scanned and delivered fast.
That is the “final mile” in practice. Regional manufacturing sites, usually built around cyclotrons, produce and dispatch doses on tight schedules. A reliable network of these sites often decides whether a patient can get a scan on a given day.
By acquiring SOFIE’s footprint, GE HealthCare gains a direct role in this stage, rather than relying only on outside partners.
What Is SOFIE Biosciences?
SOFIE Biosciences develops and delivers molecular diagnostics and therapeutics, with a focus on theranostics. Its business combines:
- A radiopharmaceutical production and distribution network across the U.S.
- Mature contract manufacturing services
- Proprietary theranostics intellectual property
SOFIE already manufactures Flyrcado™ (flurpiridaz F18 injection), a GE HealthCare product, so the two companies have an existing working relationship.
What Is FAPI-74, and Why Does It Matter?
FAPI-74 is an F18-labeled Fibroblast Activation Protein Inhibitor (FAPI) PET radiotracer currently in Phase III development. GE HealthCare already held rights outside the U.S. This deal adds the U.S. rights.
FAPI imaging targets a protein found in the tissue surrounding many tumors. That is why the agent shows promise across a wide range of cancers and potentially some non-cancer conditions, for both diagnostic and theranostic use. GE HealthCare says it aims to be among the first to launch in this fast-growing market, though FAPI-74 still needs to complete clinical development and receive regulatory approval.
Understanding the Terms
PET radiopharmaceutical (radiotracer): A radioactive imaging agent given to a patient so a PET scanner can visualize metabolic or molecular activity in the body.
CMO and CDMO: A contract manufacturing organization makes products on behalf of drug companies. A contract development and manufacturing organization also helps develop them.
Theranostics: An approach that pairs diagnosis and treatment. A radiotracer identifies a molecular target, and a related radiotherapeutic can then deliver targeted treatment to it.
Cyclotron: A particle accelerator used to produce the radioactive isotopes behind many PET agents, including F18.
What This Means for Patients and Providers
Patients should not see changes in who supplies their scans right away. The deal has not closed, and both companies have said SOFIE will keep operating as an independent manufacturing partner for its existing customers.
Over time, the deal could bring:
- More reliable supply of F18 PET agents as demand grows
- Faster access to new radiotracers as they gain approval
- Broader theranostics infrastructure, covering cyclotrons, imaging systems, digital workflow tools and radiotherapeutic manufacturing
GE HealthCare also says it will keep working with its other established CMO partners to expand access to its radiopharmaceutical portfolio.
Market Context: A Rapidly Growing Radiopharmaceutical Pipeline
The industry is expanding quickly. About 20 PET radiotracers and more than 30 radiotherapeutics are currently in development. As more targeted therapies reach the clinic, demand for dependable manufacturing and distribution is likely to rise.
GE HealthCare’s Pharmaceutical Diagnostics segment supported about 140 million imaging procedures in 2025, roughly four procedures every second, and its imaging agents have been used for over 40 years.
What Leaders Are Saying
Kevin O’Neill, President & CEO of GE HealthCare’s PDx segment, said the PET radiopharmaceutical market is expanding rapidly and that SOFIE gives GE HealthCare a way to take part across the radiopharmaceutical value chain through a mix of owned and partner facilities. He added that GE HealthCare plans to use its manufacturing experience in the U.S., Europe and Japan to invest in SOFIE.
Patrick Phelps, SOFIE co-founder, President & CEO, described joining GE HealthCare as the next step in the company’s growth, citing a shared goal of improving patient outcomes through radiopharmaceuticals.
Ted Rosenwasser, Partner at Trilantic North America, praised SOFIE’s growth and said GE HealthCare’s global expertise makes it a natural partner for the next phase.
Deal Advisors
BofA Securities, Consello Financial LLC and Solomon Partners Securities LLC served as financial advisors to GE HealthCare.
FAQs
1. How much is GE HealthCare paying for SOFIE Biosciences?
$945 million, paid in cash.
2. When will the acquisition close?
It is expected to close in the first half of 2027, subject to regulatory approvals and other conditions.
3. Who is selling SOFIE Biosciences?
Trilantic North America, a middle-market private equity firm.
4. Will SOFIE keep supplying other companies’ PET products?
Yes. SOFIE is expected to continue supplying products from other leading radiopharmaceutical providers.
5. What is a PET radiopharmaceutical CMO?
A company that manufactures and distributes radioactive imaging agents on behalf of drug developers, often through regional cyclotron sites.
6. Why do F18 PET agents need fast delivery?
F18 has a half-life of roughly 110 minutes, so doses must be produced near the point of care and delivered quickly.
7. Is FAPI-74 approved?
No. FAPI-74 is in Phase III clinical development and is not yet approved.
Disclaimer: This article is for general information only and is not medical, legal or investment advice. Details reflect the October 5, 2026 announcement; deal terms and timelines may change. Consult qualified professionals for health or financial decisions.
Official source: GE HealthCare press release